We read with great interest the article by C6te et al.' on the hemodynamic effects of amiodarone after i.v. administration in patients with coronary artery disease. The authors noted a powerful vasodilatory effect of the drug and concluded that amiodarone may also be very useful as an afterload-reducing agent in addition to its current indications. However, the afterload-reducing effect is partly due to the solvent (Tween 80) and is very transient (not longer than 5 minutes), as indicated in a letter to the editor by Breithardt, Seipel and Kuhn,2 on the basis of the results of the study by Sicart et al. 3 We are interested in another important hemodynamic effect of amiodarone: slowing in heart rate. This effect was found experimentally in animals4' and later confirmed by the early studies of i.v. amiodarone in man.6' On this basis, in the past year we used i.v. amiodarone as a negative chronotropic agent in 12 patients with acute myocardial infarction when d-blocking drugs were contraindicated. Being aware of the immediate and transient effect of the solvent Tween 80, we decided to slowly inject the drug as a bolus (5 mg/kg over 5 minutes) and then to continue a maintenance perfusion (0.6 mg/min).
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To the Editor:
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With this infusion protocol our patients did not experience hot flushes. Tachycardia, a fall in systemic pressure and rise in cardiac index did not occur. Twenty minutes after injection we observed a decrease in cardiac index, from 2.9 ± 0.59 to 2.6 ± 0.6 1/min/m2 (p < 0.01), with an increase in pulmonary wedge pressure, from 12.5 ± 4.1 to 16 ± 4.1 mm Hg (p < 0.001). Blood pressure remained unchanged and systemic vascular resistance was not significantly increased. Heart rate was decreased in all but one patient, from a mean of 111 ± 14 to a mean of 99 ± 11.8 beats/min (p < 0.001). This effect was most marked in the patients with a high initial heart rate (HR), and almost absent when the initial HR was < 80 beats/min. There is a linear correlation between the reduction in HR caused by the drug and the initial HR (r = 0.817;p < 0.001).
In the group of patients reported by C6te et al. we believe that the negative chronotropic effect of amiodarone was concealed by two factors:
(1) The initial tachycardia was probably related to the fall in blood pressure induced by a rapid injection (over a 1-minute period) of the drug plus the solvent.
(2) A linear correlation between the negative chronotropic effect of amiodarone and the initial HR exist and, moreover, this effect is observable only for an initial HR > 80 beats/min. It is difficult to accept the suggestion for the use of amiodarone intravenously as an afterload-reducing agent, if its efficacy is limited to a few minutes following rapid bolus. The drug may instead prove to be useful as a negative chronotropic and moderate negative inotropic agent in those instances when fl-blocking agents are contrain- Thus, while we agree that amiodarone normally exerts a slight dose-dependent negative chronotropic and negative inotropic action, we believe that a reduction in systemic vascular resistances is also an important property of the drug, which has been demonstrated in dogs and in humans. As a consequence of this reduction in systemic vascular resistance and reduction in afterload, cardiac output remains stable or increases in spite of the negative inotropic action of the drug. Consequently, the afterload-reducing effect of amiodarone may be beneficial, at least in some patients. Because of its potent antiadrenergic properties, amiodarone has been found very useful in several clinical situations. Peripheral vasodilatation is one of these properties and, as we have previously stated, the potential benefit of this action should be further in- 
